Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling

Prostate cancer is the most common type of cancer among men in the United States, accounting for 14% of all new cancer cases (National Cancer Institute, 2022a). Its incidence is expected to increase by about 23% between 2020 and 2040 (World Health Organization, 2023). The majority of men present with localized prostate cancer (National Cancer Institute, 2022b), but 10%–20% develop castration resistance and some progress to metastatic castration-resistant prostate cancer (mCRPC) (Kirby et al., 2011).